2025创新药高质量发展大会在广州举行 创新药发展迎新机遇

Core Insights - The 2025 Innovative Drug High-Quality Development Conference was held in Guangzhou, highlighting new opportunities for the development of innovative drugs in China [1] - Over the past decade, China's pharmaceutical innovation has progressed significantly, with over 100 overseas authorizations for innovative drugs and a total value exceeding $100 billion from January to October [1] - The development of the industry has led to improvements in clinical medication levels, medical security efficiency, and public health outcomes [1] Group 1: Government Initiatives - Guangdong Province is enhancing the entire chain of innovative drug development, establishing fast-track approval processes for eligible innovative drugs, with a review completed within 15 working days [3] - A green channel for urgently needed innovative drugs introduced through the "Hong Kong-Macao Drug and Medical Device Pass" has been established, benefiting 48 designated medical institutions and over 166 types of drugs [3] - Guangdong aims to create a multi-layered security framework for innovative drugs, promoting supplementary medical insurance for major diseases, with 1.791 million people insured in 2024, resulting in a payout of 976 million yuan [3] Group 2: Industry Confidence and Collaboration - Guangzhou Medical University Hospital shared experiences in innovative drug development and integration with commercial health insurance, emphasizing the importance of making innovative drugs accessible and reimbursable [4] - Eli Lilly's China President highlighted the company's active participation in negotiations for the national basic medical insurance directory, successfully including several innovative therapies for conditions like type 2 diabetes and blood cancers [5] - The Hong Kong Pharmaceutical Research Association is facilitating the expansion of mainland pharmaceutical companies into international markets, establishing a one-stop clinical trial resource platform and a center for drug registration to expedite processes [5] Group 3: New Drug Listings - The new basic medical insurance drug directory and the first commercial health insurance innovative drug directory were released, with 114 new drugs added to the national directory, including 50 innovative drugs, achieving an overall success rate of 88%, up from 76% in 2024 [6] - The first version of the commercial health insurance innovative drug directory includes 19 drugs [6]